CGT

554개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved554 programs
CGTCurated CoreFDAIovance BiotherapeuticsApproved

lifileucel (Amtagvi, LN-144, tumor infiltrating lymphocyte)

Unresectable or metastatic melanoma after PD-1 blockade · Polyclonal tumor neoantigens (TIL)

#PolyclonaltumorneoantigensTIL#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 47Status Approved
CGTCurated CoreFDAJohnson & JohnsonApproved

ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528)

Relapsed or refractory multiple myeloma · BCMA

#BCMA#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 29Status Approved
CGTAAVCurated CoreFDANovartisApproved

onasemnogene abeparvovec (Zolgensma, AVXS-101, onasemnogene abeparvovec-xioi)

Spinal muscular atrophy (SMA) Type 1–3, pediatric · SMN1 (AAV9)

#SMN1AAV9#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 28Status Approved
CGTAAVCurated CoreFDASarepta TherapeuticsApproved

delandistrogene moxeparvovec (Elevidys, SRP-9001, delandistrogene moxeparvovec-rokl)

Duchenne muscular dystrophy (DMD) — ambulatory / label-expanded populations · Micro-dystrophin (AAVrh74)

#Micro-dystrophinAAVrh74#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 12Status Approved
CGTCurated CoreFDAFerring PharmaceuticalsApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 10Status Approved
CGTCurated CoreFDAVertexApproved

exagamglogene autotemcel (Casgevy, exa-cel, CTX001)

Sickle cell disease with recurrent VOCs; transfusion-dependent β-thalassemia · BCL11A enhancer (CRISPR/Cas9) → HbF

#BCL11AenhancerCRISPRCas9HbF#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 9Status Approved
CGTStandard DatabasestaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
CGTStandard DatabasestaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 64Status Active
CGTStandard DatabasestaleAstraZenecaPhase 2

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Malignant Glioma; Glioblastoma · EGFR

#EGFR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 61Status Active
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleBinhui Biopharmaceutical Co., L…Phase 1

IDOV-SAFETM (Oncolytic Virus injection, Oncolytic Virus injection(IDOV-SAFETM))

Neoplasms · Neoplasms

#Neoplasms#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 59Status Recruiting
CGTLimited DatastaleMedigen Vaccine Biologics Corp.Phase 1

Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell, Recombinant Oncolytic HSV-2 Therapeutic Injecta, Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF))

Melanoma Stage IV · Melanoma Stage IV

#MelanomaStageIV#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 58Status Active
CGTLimited DatastaleMultan Medical And Dental Colle…Phase 2

Isotretinoin (Isotretinoin)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#CGT#Phase2#Popular#cell-gene-therapy+4
Trials 57Status Discontinued
CGTLimited DatastaleImmunityBio, Inc.Phase 2

ALT-803 (ALT-803)

Melanoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Discontinued
CGTStandard DatabasestaleMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTLimited DatastaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTLimited DatastaleAllife Medical Science and Tech…Phase 2

Cytokine-induced killer cells (Cytokine-induced killer cells)

Ovarian Carcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Daclatasvir-Sofosbuvir (Daclatasvir-Sofosbuvir)

Chronic Hepatitis C · Chronic Hepatitis C

#ChronicHepatitisC#CGT#Phase1#Popular#cell-gene-therapy+3
Trials 56Status Active

1 / 28 pages

← PreviousNext →